Cyclo-Oxygenase (COX) Inhibitors and Cardiovascular Risk: Are Non-Steroidal Anti-Inflammatory Drugs Really...

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Immunology

Background:

• Cyclo-oxygenase (COX) inhibitors are widely used for anti-inflammatory and analgesic purposes.
• Concerns exist regarding their association with increased cardiovascular event risk.
• Recent findings highlight potential risks even with acute COX inhibitor usage.

Purpose of the Study:

• To review preclinical and clinical literature on the cardiotoxicity of COX inhibitors.
• To explore the mechanisms underlying the cardiovascular risks associated with NSAID use.
• To propose novel factors, such as prostanoid-T cell interactions, in NSAID-associated cardiovascular disease risk.

Main Methods:

• Comprehensive review of existing preclinical and clinical studies on COX inhibitors and cardiovascular effects.
• Analysis of literature focusing on renal and vascular functions influenced by COX.
• Exploration of potential immunological interactions, specifically prostanoid and T cell pathways.

Main Results:

• Established link between COX inhibition and increased risk of coronary events.
• Contrasting evidence regarding aspirin's cardioprotective role and COX inhibition's vasodilatory effects.
• Emerging evidence suggests acute COX inhibitor use may elevate cardiovascular risk.

Conclusions:

• COX inhibitors present a complex cardiovascular risk profile.
• The role of COX in renal and vascular function is well-studied, but immunological interactions are less understood.
• Prostanoid and T cell interactions represent a potential novel mechanism mediating cardiovascular risk with NSAID use.